SELLAS Life Sciences Group, Inc. Common Stock (SLS) Financials
Key financial figures for SELLAS Life Sciences Group, Inc. Common Stock (Q2 2026).
SELLAS Life Sciences Group, Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $9.6 million, or -$0.05 per share. Free cash flow for the period was -$7.6 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for SELLAS Life Sciences Group, Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$10M
- EPS
- $-0.05
- Total Assets
- $145M
- Operating Cash Flow
- -$8M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$10M | -$0.05 | -$8M | |
| Q1 FY2026 | $0 | -$8M | -$0.05 | -$9M | |
| Q4 FY2025 | $0 | -$8M | -$0.05 | -$5M | |
| Q3 FY2025 | $0 | -$7M | -$0.06 | -$7M | |
| Q2 FY2025 | $0 | -$7M | -$0.07 | -$7M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$27M | -$0.25 | -$28M | |
| FY2024 | $0 | -$31M | -$0.50 | -$35M | |
| FY2023 | $0 | -$37M | -$1.34 | -$37M |
Frequently asked questions
What was SELLAS Life Sciences Group, Inc.'s revenue last quarter?
SELLAS Life Sciences Group, Inc. reported revenue of $0.00 for Q2 FY2026.
Is SELLAS Life Sciences Group, Inc. profitable?
Not in its most recent reported period. SELLAS Life Sciences Group, Inc. reported a net loss of $9.6 million for Q2 FY2026.
When does SELLAS Life Sciences Group, Inc. report next?
SELLAS Life Sciences Group, Inc. is scheduled to report Q3 2026 results on 2026-11-18. That date is an estimate and has not been confirmed by the company.
Full income statement, balance sheet and cash flow for SELLAS Life Sciences Group, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.